Search Press releases Keywords From To 26 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 Read More 24 Sep 2024 Transparency notification BlackRock, Inc. Read More 24 Sep 2024 UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 Read More 23 Sep 2024 UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis Read More Pagination First page Previous page Previous … Page 15 Page 16 Page 17 Page 18 Current page 19 Page 20 Page 21 Page 22 Page 23 … Page 19 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
